Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis
- PMID: 11069062
- DOI: 10.1002/1521-4141(200010)30:10<2815::AID-IMMU2815>3.0.CO;2-#
Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis
Abstract
OX40 ligand (OX40L) and OX40 (CD134) are a pair of cell surface molecules belonging to the TNF/TNF receptor family. Interaction of OX40L with its receptor OX40 is thought to be important in T cell activation through T cell/antigen-presenting cell interaction. However, involvement of these molecules in the pathogenesis of rheumatoid arthritis (RA) remains unclear. To explore the contribution of OX40/OX40L interaction to the pathogenesis of RA in vivo, we evaluated the effect of a neutralizing anti-OX40L monoclonal antibody (mAb) on the development of collagen-induced arthritis (CIA) in DBA/1 mice as an animal model for RA. Administration of anti-OX40L mAb into type II collagen (CII) -immunized DBA/1 mice dramatically ameliorated the disease severity. In vivo treatment with anti-OX40L mAb did not inhibit the expansion of CII-reactive T cells, but suppressed IFN-gamma and anti-CII IgG2a production. Therefore, OX40/OX40L interaction appears to play a critical role in the development of CIA by enhancing Th1-type autoimmune response. In addition, T lymphocytes in synovial fluid and synovial tissue from RA patients expressed OX40, while OX40L was expressed on sublining cells in synovial tissue. These results indicate that OX40/OX40L interaction may play a critical role in the development of RA.
Similar articles
-
Characterization of rat OX40 ligand by monoclonal antibody.Biochem Biophys Res Commun. 2000 Apr 21;270(3):1041-8. doi: 10.1006/bbrc.2000.2560. Biochem Biophys Res Commun. 2000. PMID: 10772947
-
CD28-independent costimulation of T cells by OX40 ligand and CD70 on activated B cells.J Immunol. 1999 Jun 15;162(12):7058-66. J Immunol. 1999. PMID: 10358148
-
Therapeutic effect of anti-OX40L and anti-TNF-alpha MAbs in a murine model of chronic colitis.Am J Physiol Gastrointest Liver Physiol. 2003 Apr;284(4):G595-603. doi: 10.1152/ajpgi.00450.2002. Epub 2003 Jan 10. Am J Physiol Gastrointest Liver Physiol. 2003. PMID: 12631559
-
OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology.Adv Immunol. 2010;105:63-98. doi: 10.1016/S0065-2776(10)05003-0. Adv Immunol. 2010. PMID: 20510730 Review.
-
Immunopathogenesis of collagen arthritis.Springer Semin Immunopathol. 2003 Aug;25(1):3-18. doi: 10.1007/s00281-003-0127-1. Springer Semin Immunopathol. 2003. PMID: 12904888 Review.
Cited by
-
Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases.Nat Rev Rheumatol. 2017 Apr;13(4):217-233. doi: 10.1038/nrrheum.2017.22. Epub 2017 Mar 9. Nat Rev Rheumatol. 2017. PMID: 28275260 Free PMC article. Review.
-
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.Ther Deliv. 2011 Jul;2(7):873-89. doi: 10.4155/tde.11.60. Ther Deliv. 2011. PMID: 21984960 Free PMC article. Review.
-
Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.Clin Exp Immunol. 2002 Oct;130(1):85-92. doi: 10.1046/j.1365-2249.2002.01962.x. Clin Exp Immunol. 2002. PMID: 12296857 Free PMC article.
-
Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis.Rheumatol Int. 2009 Feb;29(4):417-25. doi: 10.1007/s00296-008-0697-2. Epub 2008 Sep 20. Rheumatol Int. 2009. PMID: 18802705
-
Association of the co-stimulator OX40L with systemic lupus erythematosus.J Mol Med (Berl). 2009 Mar;87(3):229-34. doi: 10.1007/s00109-008-0431-2. Epub 2008 Dec 16. J Mol Med (Berl). 2009. PMID: 19083191 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical